Comparing protein patterns in skin biopsies of neurodegenerative diseases
Expression of Proteinopathies in Skin Biopsies of Patients With Neurodegenerative Disorders
This study is trying to see if the patterns of certain proteins in skin samples can help doctors better understand and diagnose different neurodegenerative diseases like Alzheimer's, Parkinson's, and frontotemporal dementia.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 45 Years and up |
| Sex | All |
| Sponsor | Universidad Autonoma de San Luis Potosí Academic / other |
| Locations | 1 site (San Luis Potosí City) |
| Trial ID | NCT06528964 on ClinicalTrials.gov |
What this trial studies
This observational study aims to analyze the aggregation patterns of specific proteinopathies, including alpha-synuclein, amyloid-beta, phosphorylated tau, and TDP-43, in skin biopsies from patients diagnosed with various neurodegenerative disorders such as Alzheimer's disease, frontotemporal dementia, and Parkinson's disease. By employing immunohistochemistry and immunofluorescence techniques, the study will compare these patterns between affected patients and healthy control subjects. The goal is to determine if distinct aggregation patterns exist for each condition, which could enhance diagnostic accuracy and understanding of these diseases.
Who should consider this trial
Good fit: Ideal candidates include men and women aged 45 and older diagnosed with Alzheimer's disease, frontotemporal dementia, Parkinson's disease, atypical Parkinsonism, amyotrophic lateral sclerosis, or normal pressure hydrocephalus.
Not a fit: Patients with a personal history of cerebrovascular disease, psychiatric disease, or those with unclear diagnoses may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic methods for neurodegenerative diseases based on skin biopsy analysis.
How similar studies have performed: While the approach of analyzing skin biopsies for neurodegenerative disease markers is relatively novel, similar studies have shown promising results in identifying proteinopathies in other tissues.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria for patients: * Patients 45 years and older * Men and women * Patients diagnosed with Alzheimer's disease, frontotemporal lobe dementia, Parkinson's disease, atypical Parkinsonism, amyotrophic lateral sclerosis or normal pressure hydrocephalus * Patients that voluntarily accept to participate in the study and accept the consent form Inclusion Criteria healthy control subjects: * People 45 years and older * Men and women * Subjects can be related to a patient but not by blood (for example spouse of a patient) * Subjects don't have direct family history of a neurodegenerative control * Subjects don't have any clinical findings suggesting dementia * Subjects voluntarily accept to participate in the study and accept the consent form Exclusion Criteria: * Patients or controls that have a personal history of cerebrovascular disease, psychiatric disease, post traumatic dementia or HIV related dementia * Patients in which the diagnosis is not clear or hasn't been confirmed * Patients or controls that have a neuroinfection * Patients or controls that a diagnosed skin disease * Patients that have an "atypical" presentation of the disease * Patients or controls that have diagnosis of a coagulopathy
Where this trial is running
San Luis Potosí City
- Hospital Central Dr. Ignacio Morones Prieto — San Luis Potosí City, Mexico (Recruiting)
Study contacts
- Study coordinator: Ildefonso Rodríguez-Leyva, MD PhD
- Email: ilrole@yahoo.com.mx
- Phone: +52 444 834 2739
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.